Tag Archives: Patent Law

END OF AN ERA – “SWISS-FORM” CLAIMS ARE OUT

Posted on February 19, 2010 by Warren Woessner

The Enlarged Board of Appeal of the EPO issued a decision on February 19th (G02/08), that Swiss-form claims will no longer be permitted as a way to claim a “second medical use” of a bioactive agent – “The use of … Continue reading →

Posted in Non-U.S. Practice | Tagged biotechnology law, EPO, Patent Law, Warren Woessner | Leave a comment

PTO Biotech/Chem/Pharma Customer Partnership Meeting Announced

Posted on February 18, 2010 by Warren Woessner

The USPTO has announced that it will hold a meeting of the Biotechnology/Chemical/Pharmaceutical Customer Partnership on Tuesday, March 2nd, in the Madison Auditorium of the USPTO in Alexandria, VA (agenda attached). You can attend in person or via a link … Continue reading →

Posted in USPTO Practice and Policy | Tagged biotechnology law, Patent Law, USPTO, Warren Woessner | Leave a comment

PTO “POINT SYSTEM” DISTRIBUTED

Posted on February 16, 2010 by Warren Woessner

I thought it worthwhile to post this “point system,” since I had never seen one before. It is encouraging that the highest tier of points an Examiner can achieve is a first office action allowance, but a little discouraging that … Continue reading →

Posted in USPTO Practice and Policy | Tagged biotechnology law, Patent Law, pto examiner, USPTO, Warren Woessner | Leave a comment

BIO Joins Stakeholders in Expressing Concerns with Efforts to Restrict Gene Patenting

Posted on February 5, 2010 by Warren Woessner

Today, the Secretary’s Advisory Committee on Genetics Health and Society (SACGHS), approved, with on dissent, a draft report which recommends legislative changes to the patent laws in regards to gene patents and recommends restrictions on licensing of federally funded research. … Continue reading →